A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil
OMS Dantas, RA de A Ximenes… - … of tuberculosis and …, 2006 - ingentaconnect.com
OMS Dantas, RA de A Ximenes, M de FPM de Albuquerque, N da Silva, UR Montarroyos…
The international journal of tuberculosis and lung disease, 2006•ingentaconnect.comSETTING: Metropolitan region of Recife, Brazil. OBJECTIVE: To estimate the additional
protection against tuberculosis (TB) provided by a second dose of bacille Calmette-Guérin
(BCG) vaccine. DESIGN: Case-control study. Cases were cases of TB newly diagnosed by
the TB control programme, independent of clinical form. Three matched neighbourhood
controls were selected using a systematic routine, starting from the case's address. The
matching was within the age groups 7–9, 10–14 and 15–19 years. RESULTS: Analysis was …
protection against tuberculosis (TB) provided by a second dose of bacille Calmette-Guérin
(BCG) vaccine. DESIGN: Case-control study. Cases were cases of TB newly diagnosed by
the TB control programme, independent of clinical form. Three matched neighbourhood
controls were selected using a systematic routine, starting from the case's address. The
matching was within the age groups 7–9, 10–14 and 15–19 years. RESULTS: Analysis was …
SETTING
Metropolitan region of Recife, Brazil.
OBJECTIVE
To estimate the additional protection against tuberculosis (TB) provided by a second dose of bacille Calmette-Guérin (BCG) vaccine.
DESIGN
Case-control study. Cases were cases of TB newly diagnosed by the TB control programme, independent of clinical form. Three matched neighbourhood controls were selected using a systematic routine, starting from the case's address. The matching was within the age groups 7–9, 10–14 and 15–19 years.
RESULTS
Analysis was conducted among 169 cases and 477 controls. For the efficacy of BCG revaccination against TB overall, matched (crude) vaccine effectiveness (VE) was −3 (95%CI −50–29) and matched (adjusted) VE was 8 (95%CI −77–52).
CONCLUSIONS
This study suggests that a second dose of BCG does not offer additional protection. Revaccination should not be offered. As large numbers of subjects are already vaccinated and vaccine appears to offer some protection in older subjects, further studies with larger sample sizes could investigate the potential efficacy of revaccination with BCG in the age group ≥15 years.
ingentaconnect.com